MarketsOperating view

A market view grounded in operating environments, not inflated market claims

The current materials support a practical reading across brachytherapy, proton innovation, LINAC QA, and protection workflows, with language support tied to domestic execution and external market dialogue rather than treated as a standalone feature.

BrachytherapyProtonLINAC QAProtection

Operating segments

Named products

Portfolio lanes

Reading frame

The market page should stay grounded in operating environments rather than unsupported TAM language.

Each segment is explained through workflow demand, visible portfolio fit, language-readiness for the readers that matter now, and what still needs future public proof.

Market posture

KOENJAES

Practical environments where the current public portfolio already reads as relevant, supported by Korean for local execution and English, Japanese, and Spanish for outward-facing dialogue.

Constraint

TAMInstalled baseRevenue

Language coverage does not imply active sales in every region, and no unsupported commercial volume, installed base, or revenue claims are added here.

Market posture

KOENJAES

Practical environments where the current public portfolio already reads as relevant, supported by Korean for local execution and English, Japanese, and Spanish for outward-facing dialogue.

Constraint

TAMInstalled baseRevenue

Language coverage does not imply active sales in every region, and no unsupported commercial volume, installed base, or revenue claims are added here.

Operating segments

Brachytherapy centers

Segment 01 / 04

Current barrier

PrecisionVerification

Brachytherapy workflows require delivery precision and dependable verification around source handling and dwell-time confidence.

Why portfolio fit exists

Brad-FIT and BIM create a visible brachytherapy-focused pair in the current public portfolio.

Current public signals

Brad-FITBIMBrachytherapy QA

Brad-FIT is presented as a treatment-side solution, while BIM is positioned as a brachytherapy QA system.

What comes next

Workflow build-outClinical context

Future site versions can add case studies or validation material when those become publicly supportable.

Operating segments

Proton innovation programs

Segment 02 / 04

Current barrier

DeliveryResearch

Proton therapy innovation conversations often need a clear technical concept and research-oriented framing.

Why portfolio fit exists

Pro-MI gives RaphaRAD a forward-looking proton therapy narrative that can speak to innovation-driven institutions.

Current public signals

Pro-MIProtonInnovation

The current site presents Pro-MI as a proton therapy technology focused on spatially fractionated narrow proton beams.

What comes next

Program stagingFuture delivery

Additional validation, publications, or institutional collaborations can be added later if disclosed.

Operating segments

LINAC QA environments

Segment 03 / 04

Current barrier

GeometryRepeatability

Routine radiation therapy operations depend on accurate alignment, isocenter checks, and repeatable QA procedures.

Why portfolio fit exists

LIM is positioned directly around linear accelerator QA tasks such as alignment and Winston-Lutz testing.

Current public signals

LIMQA launchWinston-Lutz

LIM is one of the two publicly identified QA product launches in RaphaRAD's public product record.

What comes next

Routine useOperational scale

Operational proof, deployment examples, or partner references can be added when available.

Operating segments

Protective workflow applications

Segment 04 / 04

Current barrier

PlanningProtection

Patient protection tools need to integrate into treatment setups without undermining comfort or imaging practicality.

Why portfolio fit exists

Lens-OK extends the portfolio into shielding and protection rather than keeping the company story limited to device delivery alone.

Current public signals

Lens-OKCT compatiblePatient comfort

The current site presents Lens-OK as an eye-lens shielding device with CT-compatible and patient-comfort considerations.

What comes next

Setup fitShielding use

Expanded protection workflows or implementation context can be layered in later if published.

Portfolio fit

The current product set covers more than one modality story

Each product is tied to its most visible role in the extracted site content.

Intensity-Modulated Brachytherapy System

Brad-FIT

Intensity-Modulated Brachytherapy (IMBT) system that directionally controls dose via W-shield rotation — delivering highly conformal tumor dose while minimizing OAR exposure.

Tandem applicator-based IMBT workflow for cervical and endometrial cancers+3

Tandem applicator-based IMBT workflow for cervical and endometrial cancersCylindrical applicator-based IMBT workflow for breast and vaginal cancersPrecise OAR avoidance with asymmetric dose shaping for tumors adjacent to rectum, bladder, and sigmoid colonNon-invasive, minimal-anesthesia design that reduces burden in repeated fractionated brachytherapy

Proton Minibeam Radiation Therapy

Pro-MI

Proton Minibeam Radiation Therapy (pMBRT) that reduces dose to normal tissues along the beam path while maintaining tumor control — spatially fractionated narrow beams deliver uniform dose at depth.

Proton minibeam therapy workflow that reduces normal tissue exposure along the beam path while preserving tumor treatment efficacy+3

Proton minibeam therapy workflow that reduces normal tissue exposure along the beam path while preserving tumor treatment efficacyIntegrated minibeam delivery system mountable directly onto existing proton therapy equipment nozzlesMinimizing beam-path and surrounding OAR dose for tumors adjacent to radiation-sensitive structuresLeveraging dose-volume effect and repair effect of spatially fractionated beams for normal tissue recovery

Brachy-Isotope Manager

BIM

Filmless & All-in-One — An automated QA system that verifies HDR brachytherapy source position and dwell time without film, completing verification in approximately 100 seconds.

All-in-one workflow for routine HDR QA before and after each treatment fraction+3

All-in-one workflow for routine HDR QA before and after each treatment fractionFilm-free simultaneous verification of source position and dwell time with a single deviceCompatible with major HDR systems including Elekta, Varian, and W&Z Bebig without additional setupAutomated report generation to minimize manual workload and streamline record management

Linac Isocenter Manager

LIM

One device for five LINAC QA tasks — a couch-top QA system covering laser alignment through radiation isocenter verification, completing the full workflow in under 20 minutes.

Single-device workflow covering laser alignment, isocenter, and field verification in one session+3

Single-device workflow covering laser alignment, isocenter, and field verification in one sessionRadiation-based deterministic alignment that eliminates iterative re-adjustmentQuantitative, automated radiation isocenter measurement via Winston-Lutz testSupports TG-142 daily, monthly, and annual QA checklists in one system

Eye Lens Protection Device

Lens-OK

Eye lens shielding device that efficiently attenuates electron beams during radiotherapy while maintaining high-quality CT imaging and patient comfort.

Daily lens shielding workflow for electron beam therapy (6 and 9 MeV) to minimize direct dose to the crystalline lens+3

Daily lens shielding workflow for electron beam therapy (6 and 9 MeV) to minimize direct dose to the crystalline lensTransparent silicone cover enables real-time lens monitoring during treatment; replaceable structure supports long-term hygiene and reuseDedicated CT device included for artifact-free high-quality CT imaging and accurate treatment planningFixed positioning hole prevents shield movement during treatment, ensuring reproducible setup at every fraction

Next-Generation Tumor Localization Marker

Gold-DOT

Gold powder-polymer composite marker for prostate cancer particle therapy — prototype testing confirmed 7,013 HU CT visibility, 8.5% proton and 7.2% carbon-ion dose reduction vs. up to 44.3% for pure-gold markers, with development targets of ≥7,200 HU and ≤7%.

Particle therapy tumor tracking: prototype confirmed 7,013 HU CT visibility (target ≥7,200 HU) and proton dose reduction 8.5% / carbon-ion 7.2% (target ≤7%)+3

Particle therapy tumor tracking: prototype confirmed 7,013 HU CT visibility (target ≥7,200 HU) and proton dose reduction 8.5% / carbon-ion 7.2% (target ≤7%)CT distortion pixel ratio 23% in prototype — development target ≤15% for more accurate treatment planningGold content ~1/20 of conventional pure-gold markers (prototype-confirmed) — significant cost advantage for particle therapy centersAnti-migration fixation structure ensures stable position reproducibility across all fractions

Explore Products